• MonteiroDenise Leite MaiaDLCentro Universitário Serra dos Órgãos, Teresópolis, RJ, Brasil. denimonteiro2@yahoo.com.br, Alexandre José Baptista Trajano, Daniela Contage Siccardi Menezes, Norma Luiza Machado Silveira, Alessandra Caputo Magalhães, Fatima Regina Dias de Miranda, and Barbara Caldas.
• Centro Universitário Serra dos Órgãos, Teresópolis, RJ, Brasil. denimonteiro2@yahoo.com.br
• Rev Assoc Med Bras (1992). 2013 Mar 1; 59 (2): 174180174-80.

AbstractThis study aimed to establish the safety of chemotherapy use in pregnant women with breast cancer, and to find possible effects in the fetus. A search of MEDLINE/PubMed, LILACS, SciELO, Cochrane, UpToDate, and Google Scholar databases was performed to identify publications, 86 articles published from 2001 to 2012 were retrieved and evaluated by two readers in accordance predetermined exclusion and inclusion criteria; 39 articles were selected. All the chemotherapy drugs used to treat breast cancer during pregnancy belonged to class D, and consisted of 5-fluorouracil (F), doxorubicin (A) or epirubicin (E) and cyclophosphamide (C), or the combination doxorubicin and cyclophosphamide (AC), a safe regimen when used after the first trimester of pregnancy. Few studies evaluated the use of taxanes (T), such as docetaxel (D) and paclitaxel (P), with no increase in the occurrence of fetal defects and other maternal complications when used in the second and third trimesters of pregnancy. The use of trastuzumab in pregnant women is associated with oligohydramnios and anhydramnios; thus, it is not recommended during pregnancy. As almost all studies were observational and retrospective, new prospective studies on the subject are needed.Copyright © 2013 Elsevier Editora Ltda. All rights reserved.

13 keywords...

hide…